At a glance
- Originator LEO Pharma
- Class Vitamins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Psoriasis; Renal failure
Most Recent Events
- 25 Jul 2001 Discontinued-Preclinical for Cancer in Denmark (Unknown route)
- 25 Jul 2001 Discontinued-Preclinical for Psoriasis in Denmark (Unknown route)
- 25 Jul 2001 Discontinued-Preclinical for Renal failure in France (Unknown route)